Cancer immunotherapy has emerged as a powerful treatment option characterized by durable remissions and tolerable side effects.
In recent years, an unprecedented number of immune-based therapeutic modalities have been approved in the first- and second-line as well as in the adjuvant setting across a growing number of malignancies. This influx of approvals has created a need to stay current on the latest recommendations for the appropriate application of immunotherapy.
Cancer Immunotherapy CONNECT, powered by SITC is your hub to participate in live and online educational opportunities to learn more about integrating cancer immunotherapy into your practice. Download a variety of resources in our library and connect with other clinicians in our online Community to learn more about the latest approvals, patient selection criteria, relevant biomarkers and immune-related adverse events.
SITC presents the newest in a series of videos focusing on immunotherapy for NSCLC patients, the NSCLC Immunotherapy: Advancing HopeTM video provides an overview of the building blocks of the immune system and immunotherapy, while also highlighting some of the available FDA approved immunotherapy treatments and potential side effects, and the importance of clinical trials.
View the video and then complete the companion activity for a free CME/CNE credit.
This may be due to an alternate immune checkpoint, CD200 (OX2) checkpoint blockade. The immuneosuppressive CD200 protein shuts down the immune system through multiple mechanisms (Xiong ...
While I agree with Stephanie's detailed account, simply put checkpoint molecules are a signature of exhausted/ chronically stimulated lymphocytes and therefore serves as a feedback mechanism ...
Hi Stephanie many thanks for your ample reply. It makes sense indeed in order to secure self-antigens. However, is immune system evasion by means of immune checkpoint a matter of quality ...
The expression and regulation of immune checkpoints is an area of active investigation. In answer to your question regarding whether healthy tissues express immune checkpoint ...
View More Clinician Resources
In a record display of interest and enthusiasm, more than 2,700 people attended the Society for Immunotherapy of Cancer’s (SITC) 2016 Annual Meeting & Associated Programs in National Harbor, Maryland. In this video, hear SITC 2016 delegates explain the purpose and benefits for joining thousands of their colleagues at the Annual Meeting, share how far the science of cancer immunotherapy has progressed, and predict where the field is headed. Also, learn about the benefits of becoming a member of SITC.
For more than 30 years SITC (Society for Immunotherapy of Cancer) has been fighting for treatment and a cure for cancer through research and collaboration. SITC members all over the world are leading the charge against cancer. We’re traveling the globe to meet these thought leaders and demonstrate the crucial work that they’re doing to impact advances in both the science and clinical application of immunotherapy.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com